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Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced periph-
eral neuropathy (CIPN): a secondary analysis of randomised controlled trial – CALGB/Alliance 170601
Duloxetine is an effective treatment for oxaliplatin-induced painful chemotherapy-induced peripheral
neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. The
objective of this secondary and exploratory analysis was to identify predictors of duloxetine response in
patients with painful oxaliplatin-induced CIPN. Patients (N = 106) with oxaliplatin-induced painful CIPN
were randomised to receive duloxetine or placebo. Eligible patients had chronic CIPN pain and an
average neuropathic pain score ≥4/10. Duloxetine/placebo dose was 30 mg/day for 7 days, then 60 mg/
day for 4 weeks. The Brief Pain Inventory-Short Form and the EORTC QLQ-C30 were used to assess
pain and quality of life, respectively. Univariate and multiple logistic regression analyses were performed
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to identify demographic, physiologic and psychological predictors of duloxetine response. Higher baseline
emotional functioning predicted duloxetine response (≥30% reduction in pain; OR 4.036; 95% CI 0.999–
16.308; p = 0.050). Based on the results from a multiple logistic regression using patient data from both
the duloxetine and placebo treatment arms, duloxetine-treated patients with high emotional functioning
are more likely to experience pain reduction (p = 0.026). In patients with painful, oxaliplatin-induced
CIPN, emotional functioning may also predict duloxetine response. ClinicalTrials.gov, Identifier
NCT00489411
Keywords: Duloxetine, chemotherapy-induced peripheral neuropathy, pain, oxaliplatin.
INTRODUCTION
Chemotherapy is a mainstay of cancer treatment that is
received by millions of cancer survivors. Chemotherapy-
induced peripheral neuropathy (CIPN) is a common side
effect of neurotoxic chemotherapeutic agents such as
oxaliplatin, and many others (Argyriou et al. 2010; Beijers
et al. 2014). Numbness and tingling in the hands and feet
are the most common symptoms and CIPN becomes
chronically painful in approximately 20–42% of cases
(Dworkin 2002; Cavenagh et al. 2006; Hausheer et al.
2006; Taylor 2006; Argyriou et al. 2008a, Windebank &
Grisold 2008; Smith et al. 2010; Sonneveld & Jongen
2010; Kautio et al. 2011; Geber et al. 2013). Conse-
quently, CIPN can evolve into a chronic pain syndrome
that impairs function and quality of life (QOL) (Calhoun
et al. 2003; Cella et al. 2003; Almadrones et al. 2004; Bak-
itas 2007; Bruner et al. 2007; Kiser et al. 2010; Tofthagen
2010; Plotti et al. 2011; Mols et al. 2014).
Unfortunately, evidence-based, effective interventions
for painful CIPN are rare. Duloxetine, a serotonin–nore-
pinephrine reuptake inhibitor, is the only recommended
treatment for painful oxaliplatin-induced CIPN (Hersh-
man et al. 2014). Duloxetine works by increasing the
amount of key pain-inhibiting neurotransmitters, sero-
tonin and norepinephrine, within the central nervous sys-
tem (Bymaster et al. 2003). Although the original
randomised, placebo-controlled trial conducted by the
Cancer and Leukemia Group B (CALGB) provides strong
evidence of duloxetine efficacy, just 33% of the dulox-
etine-treated patients experienced a moderate pain reduc-
tion (≥30%), and even fewer (21%) experienced a
substantial decrease in pain (≥50%) (Smith et al. 2013).
Moreover, duloxetine was ineffective in 41% of the study
participants (Smith et al. 2013). Since duloxetine was not
completely effective, nor did it work for everyone, identi-
fying predictors of duloxetine response is a priority area
for future research. More specifically, if we know why
duloxetine works, for whom and in what circumstances, a
personalised approach can be used to prescribe duloxetine
to those most likely to benefit.
A clue regarding one possible predictor of duloxetine
response can be found in the original report of the
CALGB study (Smith et al. 2013). More specifically, the
results of an exploratory responder analysis suggest that
patients with oxaliplatin-induced painful CIPN are more
likely to experience a benefit from duloxetine than
patients with paclitaxel-induced CIPN (Smith et al.
2013). This finding suggests that duloxetine’s mecha-
nism of action may be uniquely tied to very specific
mechanisms of chemotherapy-induced neurotoxicity.
Although the precise mechanism of chronic oxaliplatin-
induced CIPN is still unknown, studies have shown
that oxaliplatin accumulates in the dorsal root ganglion
where it causes nerve cell apoptosis (Cavaletti et al.
2001; Renn et al. 2011). In addition, an oxaliplatin
metabolite, oxalate, chelates calcium and impairs cal-
cium-sensitive sodium-dependent ion channel function,
leading to peripheral nerve hyper-excitability (Grolleau
et al. 2001; Wilson et al. 2002; Krishnan et al. 2005;
Benoit et al. 2006; Park et al. 2009; Beijers et al. 2014).
In contrast, taxanes disrupt microtubules, causing CIPN
by subsequent demyelination and impairment of axonal
transport (Persohn et al. 2005; Argyriou et al. 2008b;
Park et al. 2011). Other taxane-induced nerve injury
mechanisms include macrophage activation in periph-
eral nerves and dorsal root ganglia, microglial activation
and down-regulation of glutamate transporters in the
spinal cord, and damaged mitochondria in A- and C-
fibres (Cata et al. 2006; Flatters & Bennett 2006; Peters
et al. 2007; Argyriou et al. 2008b, 2012; Jin et al. 2008).
We found no other published studies exploring a differ-
ential response to duloxetine based on the causative
chemotherapeutic agent; more research in this area is
needed.
The chronic pain literature provides additional clues
about other possible predictors of duloxetine response.
Widespread body pain, emotional distress (e.g., anxiety,
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depression), fatigue, impaired cognition, and sleep dis-
turbance are centrally mediated symptoms that co-occur
in a variety of chronic pain conditions and predict pain
severity (Clauw & Chrousos 1997; Fukuda et al. 1997,
1998; Clark et al. 2000; Bair et al. 2003; Giesecke et al.
2003; Gore et al. 2005, 2006; Heitkemper & Jarrett
2005; Postma et al. 2005; Castillo et al. 2006; Zelman
et al. 2006; Bakitas 2007; Geisser et al. 2007, 2008a,b;
Allen et al. 2008; Clemens et al. 2008; Fishbain et al.
2008; Roy-Byrne et al. 2008; Zhang & Jordan 2008; War-
ren et al. 2009; Desaulniers 2011; Tofthagen 2011;
Geber et al. 2013). Individuals with painful CIPN also
experience similar centrally mediated symptoms (Nail
2011; Tofthagen et al. 2013). Since co-occurring symp-
toms can make chronic pain worse, patients with pain-
ful CIPN who also experience co-occurring symptoms
may be less responsive to analgesic interventions like
duloxetine. Accordingly, this paper reports the results of
secondary and exploratory analyses (using data from the
CALGB trial) that were performed to determine whether
the European Organisation for the Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) subscale scores for emotional and cognitive
functioning, fatigue and insomnia would predict dulox-
etine response in the CALGB patient cohort that experi-
enced the best effect – those with oxaliplatin-induced
CIPN. The primary hypothesis is that baseline severity
of co-occurring symptoms common to chronic pain dis-
orders – emotional distress, impaired cognition, fatigue,
and insomnia – will predict duloxetine efficacy in
patients with chronic, painful oxaliplatin-induced CIPN.
METHODS
Sample and setting
Between April 2008 and March 2011, CALGB 170601
enrolled 231 participants ≥25 years of age from 105 aca-
demic and community sites throughout the United States.
All patients provided signed Institutional Review Board-
approved informed consent. Patient eligibility has been
previously described (Smith et al. 2013). Briefly, eligible
participants reported sensory neuropathy >grade 1 using
the National Institutes of Health Common Terminology
Criteria for Adverse Events (CTCAE) v. 3.0 grading scale,
an average CIPN-related neuropathic pain score ≥4 on a 0–
10 scale using the Brief Pain Inventory-Short Form (BPI-
SF) item 5, and persistent pain at least 3 months after
completion of paclitaxel or oxaliplatin treatment. Patients
could not have received other types of neurotoxic
chemotherapy drugs (e.g. vinca alkaloids, bortezomib,
thalidomide), and those with neuropathy due to other
comorbid conditions were not eligible. Concurrent use of
other antidepressants, anticonvulsants, high-dose vitamin
supplements or drugs known to influence serotonin levels
(e.g. tramadol) was not allowed.
Procedure
The research methods used in CALGB 170601 have been
previously described (Smith et al. 2013). Eligible partici-
pants were randomised to receive either duloxetine 60 mg
or placebo. Stratified, random assignment to treatment
groups was determined by the CALGB/Alliance Statistics
and Data Center based on the neurotoxic drug received
(taxane versus platinum) and CIPN risk [high risk (those
with diabetes mellitus) versus low risk]. All patients and
personnel were blinded to treatment assignment.
Duloxetine/placebo was started at 30 mg daily for the
first week. Beginning on day 8, 4 weeks of full dose
(60 mg) duloxetine/placebo treatment began. Starting at
week 6, participants underwent a 2-week washout period
and then crossed over to the other treatment arm.
A clinical research associate telephoned each patient
weekly to ask them to rate CIPN pain severity using the
BPI-SF. The BPI-SF is a well-validated 15-item instrument
that includes items quantifying average, worst, least and
immediate pain severity using a 0–10 numeric rating scale
(Cleeland et al. 1994; Cleeland 2009). The BPI-SF has been
tested in culturally and linguistically diverse populations
with various types of painful disorders, providing evidence
of internal consistency and test–retest reliability, and con-
struct, structural, concurrent and discriminant validity
(Cleeland 2009). BPI-SF item #5, which quantifies average
pain severity using a 0–10 scale, was used to assess dulox-
etine response.
Participants also completed the EORTC QLQ-C30 on
day 1 of weeks 1, 6, 8 and 13. The EORTC QLQ-C30 is
comprised of several core components applicable to all
cancer patients (Aaronson et al. 1993). Its 30 items are
grouped into subscales assessing global health status and
QOL (2); physical (5), role (2), emotional (4), cognitive (2)
and social (2) functioning; fatigue (3); nausea and vomiting
(2); and pain (2). The questionnaire assesses six additional
items: dyspnoea, insomnia, appetite loss, constipation,
diarrhoea and financial difficulties. Respondents rate their
global health status and QOL from 1 (very poor) to 7 (ex-
cellent). The degree to which respondents are experiencing
other problems is rated on a 4-point Likert scale, ranging
from ‘Not at All’ to ‘Very Much’. For the current analysis,
we focused on specific subscales known to be associated
with chronic pain: emotional and cognitive functioning,
fatigue, pain and insomnia. The emotional subscale items
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quantify whether the respondent worries, or feels tense,
irritable or depressed. Items in the cognitive function sub-
scale assess concentration and memory. The fatigue sub-
scale asks about weakness, the need for rest and feeling
tired. Two pain subscale items ask if respondents have
had pain and about pain’s influence on performance of
daily activities. The insomnia question quantifies
whether the respondent has had trouble sleeping. Cron-
bach’s alpha coefficients for the global health status, emo-
tional and cognitive functioning, fatigue and pain
subscales range from 0.73 to 0.89 (Aaronson et al. 1993).
Test–retest reliability correlations range from 0.70 to 0.90
for all subscales (Hjermstad et al. 1995). Satisfactory con-
struct validity has been previously demonstrated (Aaron-
son et al. 1993).
Analyses
Given the exploratory nature of the analyses, an a priori
power analysis was not conducted. However, to min-
imise the risk of false discovery, all analyses were con-
ducted using data obtained only from oxaliplatin-treated
patients in the initial treatment period (weeks 1–5),
because the subgroup analysis for the paclitaxel cohort
did not yield significant differences in pain reduction. A
post hoc power analysis revealed that there would be
60% power (two-sided inflated alpha of 0.10) to detect
predictors of duloxetine response if 25% of patients
responded in the below-median group versus 53% of
those in the above-median group. Statistical analyses
were performed by the Alliance Statistics and Data Cen-
ter, using SAS 9.3 (Cary, NC) on a database locked in
April 2012.
We focused on exploring whether EORTC QLQ-30 sub-
scale scores quantifying known predictors of chronic pain
severity (emotional function, impaired cognition, fatigue
and insomnia) might predict duloxetine response, defined
as a ≥ 30% improvement (Dworkin et al. 2009) in pain
severity during the initial treatment period based on the
pain score obtained from BPI-SF item # 5. Differences in
demographic variables between duloxetine and placebo
arms were compared using t-tests for continuous variables
and chi-squared tests or Fisher’s exact tests for categorical
variables (Fleiss 1981; Altman 1991). Descriptive statistics
[medians, frequencies, 95% confidence intervals (CI)] were
calculated to describe the incidence of duloxetine
response by chemotherapy agent. Young/old age and low/
high EORTC QLQ-30 subscale scores were defined based
on medians of the distributions. Changes in EORTC sub-
scale scores were summarised using means and standard
deviations (SDs), and compared by general linear mod-
elling adjusted for baseline score and neuropathy risk
(presence/absence of diabetes). High/low subscale scores
were defined as being either above or below the medians.
Univariate and multiple logistic regression analyses
were performed to identify predictors for duloxetine
response. To test for an interaction effect of emotional
functioning and treatment arm, we constructed a multiple
logistic regression model (controlling for baseline CTCAE
neuropathy grade) using patient data from the duloxetine
and placebo treatment arms. Odds ratios for the selected
baseline EORTC QLQ-30 subscales scores were calculated
using the scores between 0 and 100 and divided by 331/3.
This rescales the scores back to the original range for ease
of interpretation. The odds ratio for global health status
was calculated based on the actual scores. The proportion
of missing data was ≤4% for the primary outcome; there-
fore, we took a complete case analysis approach. To test
for a treatment group effect on the change in EORTC
QLQ-C30 subscale scores during the initial treatment per-
iod, we used analysis of covariance, each stratified by neu-
rotoxic agent and comorbid risk (presence/absence of




Patients’ demographic characteristics (Table 1) were
derived using data obtained only from the patients with
oxaliplatin-associated painful CIPN (n = 106; duloxetine
n = 49; placebo n = 57). The oxaliplatin sample was pri-
marily men (64.2%) and Caucasian (85.9%). Most
patients had good performance status (85.9%) and had
undergone chemotherapy treatment for a stage I–III
(79.2%) gastrointestinal malignancy (98.1%). The mean
age was 59.7 years, and the mean baseline pain score
was 5.8 out of 10. With the exception of the baseline
neuropathy grade (duloxetine group mean grade = 2.35,
SD 0.52); placebo group mean grade = 2.26, SD 0.41), no
statistically significant differences in demographic char-
acteristics between the duloxetine- and placebo-treated
groups were found.
Incidence of duloxetine response
Table 2 illustrates the incidence of duloxetine respon-
ders in the oxaliplatin-treated cohort. To avoid the risk
of false discovery due to multiple testing, statistical
tests were not performed using these data. Nevertheless,
the findings support the hypothesis that patients with
more severe symptoms are less likely to benefit from
4 of 11 © 2015 John Wiley & Sons Ltd
SMITH ET AL.
duloxetine. The biggest differences in duloxetine
response were seen when examining the percentage of
responders experiencing high versus low emotional func-
tioning, fatigue and pain. Approximately 28% more
patients with high versus low emotional functioning
responded to duloxetine. Furthermore, when compared
to patients with higher levels of fatigue and pain, more
patients with low scores, 25.5% and 23.8% respectively,
responded to duloxetine.
EORTC QLQ-C30 subscale scores
Table 3 presents the change from baseline to 6-week
EORTC QLQ-C30 subscale scores in duloxetine- and pla-
cebo-treated patients. After adjusting for the baseline pain
score and CIPN risk (presence/absence of diabetes), dulox-
etine-treated patients reported a greater improvement in
global health (p = 0.005), cognitive function (p = 0.021)
and pain (p = 0.020) than did placebo-treated patients.
Predictors of duloxetine response
The results of a univariate logistic regression, presented in
Table 4, suggest that patients with better baseline emo-
tional functioning scores were four times more likely to
respond to duloxetine treatment (OR 4.036; 95%CI 0.999–
16.308; p = 0.050). Baseline cognition, fatigue and insom-
nia scores did not predict duloxetine response. Based on
the results from amultiple logistic regression using patient
data from both the duloxetine and placebo treatment arms,
the interaction p-value of emotional functioning and treat-
ment arm (duloxetine versus placebo) was 0.026, suggest-
ing that duloxetine-treated patients with oxaliplatin-
induced CIPN pain and high emotional functioning are
more likely to obtain a ≥ 30% reduction in pain.
DISCUSSION
Based on the results of a recently published systematic
review of randomised controlled trials testing CIPN inter-
ventions, duloxetine is the only drug recommended for
the treatment of chronic CIPN pain (Hershman et al.
2014). As expected, duloxetine is not universally effective
(Smith et al. 2013), and the reasons for its selective effi-
cacy are unknown. The results of these secondary and
exploratory analyses suggest that patients with better
baseline emotional health (feeling less worried, tense, irri-
tated, depressed) are four times more likely to respond to
duloxetine, suggesting that those whose pain is part of a
larger symptom cluster may benefit the least. These find-
ings are consistent with the results of many studies show-
ing that anxiety predicts pain perception (Theunissen
et al. 2012; Schreiber et al. 2013; Bruce et al. 2014; Mias-
kowski et al. 2014). One such study reported that patients
who were more anxious were more likely to have painful
versus non-painful CIPN (Geber et al. 2013). Their find-
ings reinforce what is known about the relationship
between anxiety and pain and suggest that the patients in
our study with high emotional functioning scores
responded better to duloxetine because they were less wor-
ried and tense – emotions/feelings which are similar to
anxiety. The implication for clinical practice is that per-
haps emotionally distressed/anxious patients should be
offered anxiety-relieving interventions alongside duloxe-
tine.
Table 1. Demographics characteristics
Characteristics









30–39 0 (0) 1 (1.8) 1 (0.9) 0.882*
40–49 6 (12.2) 11 (19.3) 17 (16.0)
50–59 22 (44.9) 20 (35.1) 42 (39.6)
60–69 16 (32.7) 15 (26.3) 31 (29.3)
≥70 5 (10.2) 10 (17.5) 15 (14.2)
Mean (SD) 59.86 (9.52) 59.56 (10.97) 59.70 (10.28)
Sex
Men 28 (57.1) 40 (70.2) 68 (64.2) 0.163
Women 21 (42.9) 17 (29.8) 38 (35.8)
Race
White 43 (87.8) 48 (84.2) 91 (85.9) 0.547
Black 5 (10.2) 4 (7.0) 9 (8.5)
Other 1 (2.0) 3 (5.3) 4 (3.8)
Not reported 0 (0) 2 (3.5) 2 (1.9)
High risk of chemotherapy-induced peripheral neuropathy
No 22 (44.9) 26 (45.6) 48 (45.3) 0.941
Yes 27 (55.1) 31 (54.4) 58 (54.7)
Primary disease
GI 48 (98.0) 56 (98.2) 104 (98.1) 1.000
Other 1 (2.0) 1 (1.8) 2 (1.9)
Disease stage
Early I–II 10 (20.4) 15 (26.3) 25 (23.6) 0.604
III 27 (55.1) 32 (56.1) 59 (55.7)
Metastatic 12 (24.5) 10 (17.5) 22 (20.8)
Performance status
0 26 (53.1) 29 (50.9) 55 (51.9) 1.000
1 22 (44.9) 26 (45.6) 48 (45.3)
2+ 1 (2.0) 2 (3.5) 3 (2.8)
Sensory neuropathy grade†
Mean (SD) 2.35 (0.52) 2.26 (0.41) 2.25 (0.47) 0.040*
Baseline pain score
<4 1 (2.0) 0 (0) 1 (0.9) 0.189*
4–5 19 (38.8) 32 (56.1) 51 (48.1)
6–7 19 (38.8) 18 (31.6) 37 (34.9)
8–10 10 (20.4) 7 (12.3) 17 (16.0)
Mean (SD) 6.00 (1.70) 5.58 (1.58) 5.77 (1.64)
*Tested as a continuous variable.
†Based on National Cancer Institute Common Terminology for
Adverse Events (NCI-CTCAE) Sensory Neuropathy Grade.
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We found no other published studies designed to explore
whether a patient profile predicts the likelihood of clini-
cally meaningful duloxetine-induced pain relief in
patients with CIPN. However, two studies of duloxetine
response in patients with other chronic pain conditions
(migraine headache, fibromyalgia) who received similar
doses suggest that patients with more severe baseline anx-
iety and depression were more likely to respond (Taylor
et al. 2007; Marangell et al. 2011). In the current study,
those with better emotional functioning were more likely
to achieve at least a 30% reduction in pain. Our findings
may vary from those of other published chronic pain stud-
ies due to differences in underlying pain and stress mecha-
nisms in patients with non-malignant pain versus cancer
treatment-related pain. In addition, these discordant
results may stem from variations in measurement
approaches. For this secondary data analysis, emotional
functioning was quantified using a four-item EORTC
QLQ-30 subscale that assessed the degree to which the
patient felt worried, tense, irritated or depressed. Because
the EORTC QLQ-30 subscale quantifies a different emo-
tional phenotype than instruments designed to diagnose
mood disorders (anxiety and depression), the current find-
ings are not directly comparable with other chronic pain
studies.
An alternative explanation for the difference in dulox-
etine response rates may be related to differences in
patients’ underlying pain mechanisms. For example, some
patients may have pain caused by multiple/mixed mecha-
nisms, both peripheral nociceptive and central neuro-
pathic. This idea is supported by Geber et al. (2013), 60%
Table 2. Incidence of responders*
Variable Median
Duloxetine (n = 49) Placebo (n = 57)
# Responders/Total n % Responders (95% CI) # Responders/Total n % Responders (95% CI)
Age
Younger 59.2 8/23 34.8 (16.4–57.3) 4/30 13.3 (3.8–30.7)
Older 13/26 50.0 (29.9–70.1) 4/27 14.8 (4.2–33.7)
Gender
Male 11/28 39.3 (21.5–59.4) 6/40 15.0 (5.7–29.8)
Female 10/21 47.6 (25.7–70.2) 2/17 11.8 (1.5–36.4)
Global health status
Low 66.6 9/26 34.6 (17.2–55.7) 4/23 17.4 (5.0–38.8)
High 12/22 54.6 (32.2–75.6) 4/34 11.8 (3.3–27.5)
Emotional functioning
Low 75.0 4/16 25.0 (7.2–52.4) 5/25 20.0 (6.8–40.7)
High 17/32 53.1 (34.7–70.9) 3/32 9.4 (2.0–25.0)
Cognitive functioning
Low 83.3 9/21 42.9 (21.8–66.0) 4/23 17.4 (5.0–38.8)
High 12/27 44.4 (25.5–64.7) 4/34 11.8 (3.3–27.5)
Fatigue
Low 33.3 10/17 58.8 (32.9–81.6) 2/21 9.5 (1.2–30.4)
High 10/30 33.3 (17.3–52.8) 6/36 16.7 (6.4–32.8)
Pain
Low 50.0 12/21 57.1 (34.0–78.2) 2/19 10.5 (1.3–33.1)
High 9/27 33.3 (16.5–54.0) 6/38 15.8 (6.0–31.3)
Insomnia
Low 33.3 4/11 36.4 (10.9–69.2) 2/14 14.3 (1.8–42.8)
High 17/37 46.0 (29.5–63.1) 6/43 14.0 (5.3–27.9)
*Responders = ≥30% improvement in pain score during initial treatment period based on the pain score from BPI-SF item # 5. EORTC
QLQ-30 subscale scores are baseline measurements obtained at week 1 of the initial treatment period. Young/old age and low/high
scores are defined based on medians of the distributions.











pMean SD N Mean SD N
Global health
status
8.1 23.1 44 3.8 18.0 50 0.005*
Emotional
functioning
6.8 16.2 44 3.7 17.3 50 0.074
Cognitive
functioning
7.6 18.1 44 0.67 16.8 50 0.021*
Fatigue 3.6 23.7 43 3.3 16.5 50 0.725
Pain 9.8 24.2 44 4.1 16.5 49 0.020*
Insomnia 3.0 21.3 44 0.0 26.1 50 0.547
Change scores were calculated by subtracting baseline from
week 6 subscale scores obtained only in the sample of patients
who provided a week 6 score.
*Greater improvement in duloxetine-treated patients than pla-
cebo-treated patients.
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of whose study subjects with painful CIPN also reported
pain with musculoskeletal (nociceptive) characteristics.
Perhaps non-responding CALGB 170601 participants
experienced more nociceptive pain due to musculoskele-
tal symptoms, multiple surgeries, or radiation therapy.
Since nociceptive/peripheral pain is less responsive to cen-
trally acting drugs like duloxetine, a higher incidence of
mixed pain in non-responding patients might partially
explain duloxetine’s selective efficacy.
Given these considerations, the cause of duloxetine’s
selective effect may lie within the central nervous system.
Although not well understood, mechanisms involved in
the development of chronic neuropathic pain include
abnormal neuron receptors and ion channel function,
increased production and release of pain-facilitating neuro-
transmitters, and faulty central nervous system-mediated
pain excitatory and inhibitory systems (Baron et al. 2010).
A study conducted in patients with painful diabetic neu-
ropathy provides preliminary evidence that inefficient cen-
tral nervous system-mediated pain inhibition – mediated
by serotonin and norepinephrine – predicts better dulox-
etine response (Yarnitsky et al. 2012). This finding sug-
gests that duloxetine may be less effective for patients
with normally functioning pain inhibitory systems.
This study has several limitations. First, although the
results suggest that better emotional health was the only
hypothesised variable that predicts duloxetine response,
the sample size of responders may have been too small to
detect statistically significant associations between base-
line cognitive functioning, fatigue, and insomnia subscale
scores and duloxetine response. In addition, we hypothe-
sised that the EORTCQLQ-C30 subscale scores for factors
known to be associated with chronic pain severity in other
populations – emotional and cognitive functioning, fati-
gue and insomnia –would be most closely associated with
duloxetine response. However, other well-known predic-
tors of chronic pain severity were not assessed, such as
previous trauma exposure (e.g., sexual/physical abuse,
physical trauma, deployment to war) (Campbell & Lewan-
dowski 1997; Golding 1999; Coker et al. 2000; Baccini
et al. 2003; Meltzer-Brody et al. 2007; Humphreys et al.
2010; Barry et al. 2011; Raphael & Widom 2011) and the
tendency to catastrophise about pain (believing that pain
is profoundly awful) (Sullivan et al. 2001; Edwards et al.
2006, 2011; Campbell & Edwards 2009). EORTC QLQ-
C30 subscale scores, used to quantify the predictor vari-
ables, may be less sensitive than other validated measures
of psychological and physical symptoms. Last, although
patients in the duloxetine group were taking fewer con-
comitant analgesics than the placebo-treated patients at
baseline and at study completion, analgesic dosage in the
oxaliplatin group could have increased over the initial
treatment period, accounting for improvements in pain.
These possible changes in concomitant analgesic dosage
were not quantified (Smith et al. 2013).
The findings of this secondary data analysis suggest
that patients with better baseline emotional functioning
may be more likely to benefit from duloxetine. The next
step is to conduct adequately powered follow-up studies
to confirm these findings, and to identify other predictors
of duloxetine response that might be amenable to com-
plementary interventions. Patients with greater emo-
tional distress and other sources of pain (muscle/joint
pain associated with endocrine therapy for breast cancer)
may require additional pharmacologic and/or non-phar-
macologic interventions combined with duloxetine in
order to achieve clinically significant improvements in
pain. Thus, uncovering a patient phenotype associated
with duloxetine efficacy could help clinicians make more
informed decisions about who should receive the drug,
and which patients may benefit from multi-modality
treatments.














62.0 22.1 1.015 0.99–1.04 0.310
Emotional
functioning
78.3 15.4 4.036 0.99–16.31 0.050^
Cognitive
functioning
80.6 17.0 1.286 0.41–4.01 0.665
Fatigue 35.7 23.6 0.526 0.22–1.29 0.159
Pain 45.8 28.2 0.749 0.38–1.50 0.412




62.6 20.1 0.980 0.94–1.02 0.266
Emotional 72.1 23.7 0.577 0.21–1.55 0.276
Cognitive 77.5 19.5 0.779 0.22–2.73 0.696
Fatigue 33.9 22.9 1.879 0.67–5.26 0.230
Pain 52.3 23.9 1.308 0.46–3.73 0.615
Insomnia 39.2 31.6 0.935 0.42–2.09 0.870
Duloxetine response = ≥30% improvement in pain score during
initial treatment period based on the pain score from BPI-SF
item #5.
*Odds ratios for EORTC QLQ-30 function and symptom scores
are calculated based on the scores divided by 331/3; odds ratio
for global health status is calculated based on the scores. ^Based
on the results from a multiple logistic regression using patient
data from both treatment arms (duloxetine and placebo) and
adjusting for baseline neuropathy severity, the interaction p-
value of emotional functioning and treatment arm was 0.026.
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